Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 48

Results For "Business"

2475 News Found

Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY
News | February 02, 2026

Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY

Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%


Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
Policy | February 01, 2026

Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan

The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave


Budget 2026–27: Rs. 1,06,530.42 crore allocated to Ministry of Health and Family Welfare
Policy | February 01, 2026

Budget 2026–27: Rs. 1,06,530.42 crore allocated to Ministry of Health and Family Welfare

The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education


Astec LifeSciences posts robust Q3 growth
News | January 31, 2026

Astec LifeSciences posts robust Q3 growth

The company’s total income jumped 31% year-on-year to Rs 125.5 crore


Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%
News | January 30, 2026

Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%

The base Gland business posted ?11,790 million in revenue, up 16% YoY


AstraZeneca pledges $15 billion investment in China through 2030
News | January 30, 2026

AstraZeneca pledges $15 billion investment in China through 2030

UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."


Lonza posts CHF 6.5 billion in 2025 sales, marks strong profit growth
News | January 30, 2026

Lonza posts CHF 6.5 billion in 2025 sales, marks strong profit growth

Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model


Mabtech & Sai Life Sciences launch strategic collab to revolutionize immunology research
R&D | January 30, 2026

Mabtech & Sai Life Sciences launch strategic collab to revolutionize immunology research

EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time


Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%
News | January 30, 2026

Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%

The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year